Condition
Allosensitization
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 1 (3)
P 4 (1)
Trial Status
Completed2
Withdrawn2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03689075Phase 4Terminated
Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation
NCT05862766Early Phase 1Withdrawn
Isatuximab in Lung Transplant Recipients
NCT04610320Phase 1CompletedPrimary
Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation
NCT04204980Phase 1CompletedPrimary
Desensitization in Kidney Allograft Using Daratumumab
NCT04088903Phase 1WithdrawnPrimary
Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
Showing all 5 trials